Introduction

The fixed-dose combination of the four drugs elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (trade name: Stribild) has been approved in Germany since October 2017 for the treatment of HIV type 1 in teenagers over the age of 12. The fixed-dose combination is an option if medication without the drug tenofovir disoproxil can't be used due to side effects.

The human immunodeficiency virus (HIV) multiplies in cells of the immune system and destroys them. Without proper treatment, the immune system of most HIV patients is weakened so much that they become seriously ill. This stage is referred to as AIDS (acquired immune deficiency syndrome).

Although the currently available medications can't cure HIV, they can prevent immunodeficiency for many years. But the medication can become ineffective over time, allowing the viruses to multiply more again.

Application

The fixed-dose combination including elvitegravir is taken in the form of a tablet, once a day with a meal. One tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil.

Other treatments

Teenagers with HIV are generally given individually tailored treatment for HIV. This type of treatment takes into consideration factors like which treatments were tried before and why they were stopped. For instance, the previous treatment may not have worked or may have caused side effects.

Assessment

In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to find out whether the fixed-dose combination of elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil has any advantages or disadvantages compared with standard treatments for HIV type 1 in teenagers.

But the manufacturer didn't provide any data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of this review and the hearings received, the G-BA passed a resolution on the added benefit of elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (Stribild).